Share this page
www.indivumed.com/pipeline/

Our rapidly growing pipeline

We aim for first-in-class therapeutics. For promising target candidates, we have developed high-throughput screening assays and entered the drug discovery phase. Assets are available for licensing or provide a foundation for R&D partnerships to bring novel therapeutics successfully to the market.

Indivumed Pipeline

Target
Indication
Discovery & Validation - Assay Development
Hit to Lead
IND
IN2401
CRC
Discovery & Validation
Hit to Lead
IND
IN2402
CRC
Discovery & Validation
Hit to Lead
IND
IN2403
CRC
Discovery & Validation
Hit to Lead
IND
IN2501
CRC
Discovery & Validation
Hit to Lead
IND
Multiple
Various
Discovery & Validation
Hit to Lead
IND

Do you want to learn more?

Get in touch if you are interested in details of our current and future pipeline, ongoing development programs, or additional indications. We are happy to discuss a potential collaboration.

Last updated:

Our Pipeline What makes our assets stand out?

Our targets are the result of a patient-centric approach that is truly unique from the very first step. Starting with nonischemic, highly standardized tumor samples from patients all over the world, we create proprietary multi-omics datasets. In our holistic target identification and validation process, we utilize this data as well as the source samples to enhance the probability of successful therapeutic development.

Unique multi-omics data from fully standardized and carefully curated patient samples

A cutting-edge biomathematical and bioinformatic target ID approach

Highly reliable target validation using patient-derived 2D and 3D tumor models

Each factor adds to an unrivaled capacity to reduce risk in novel drug development

“Our R&D approach brings novel insights through our unique starting point. Carefully collected and curated patient samples are excellent representations of the characteristic features of the disease, making the difference in target discovery and lead generation toward innovative and successful therapeutics.”

Prof. Dr. Anton Wellstein | Chief Scientific Officer, Indivumed